- Real-world use, effectiveness, safety of anti-viral treatment in chronic hepatitis C genotype 3 by M. Cornberg, et al.
Summary: This study looked at the effectiveness and predictors of taking pegylated interferon with ribavirin (PR) and patients taking sofosbuvir (SOF) and PR. SVR ranged from 80.9% in the PR group to 96.1% in PR+SOF treated patients. Treatment-experienced patients with cirrhosis showed a suboptimal SVR of 68% for SOF+RBV but a high SVR of 90–95% for Daklinza+SOF±RBV. The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV based regimens.
- Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt by A. Eisharkawy, et al.
Summary: This study looked at the effectiveness and predictors of taking sofosbuvir and ribavirin for 6 months versus taking the treatment sofosbuvir with pegylated interferon with ribavirin for 3 months. Group one achieved a 94% cure rate. In group two 78.7% achieved SVR. These results were similar to those achieved in other clinical trials.
- Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial by Eric Lawitz, et al.
Summary: Combining different DAAs with a variety of mechanisms may help shorten required treatment durations. This study aimed to find the treatment combination promising the best results the fastest. The study gave patients elbasvir/grazoprevir and sofosbuvir for 4-12 weeks. Patients being retreated were given the compound with ribavirin for 12 weeks. Cure rates were as follows:
|Without liver cirrhosis hep C genotype 1||4||32%|
|With liver cirrhosis hep C genotype 1||4||80%|
|Without liver cirrhosis hep C genotype 3||6||93%|
|With liver cirrhosis hep C genotype 3||12||83%|
Summary: By examining a database of all of those tested for HCV or HIV at the British Columbia Centre for Disease Control Public Health Laboratory during 1990–2013, the researchers found that 8% of patients were reinfected; 11% after spontaneous clearance, 2% after achieving SVR. They found that the incidence of HCV reinfection was higher among HIV co-infected individuals, those who spontaneously cleared HCV infection, and PWID.
- Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial by Meike H van der Ree, et al.
Summary: This clinical trial looked at the safety and effectiveness of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucleotide. The trial showed that RG-101 could achieve SVR after 4 weeks of treatment.
Recent Press Releases by Pharmaceutical Companies
- Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR Rates in Genotype 1 Japanese Patients
|GT1 without cirrhosis, some with the resistance-associated Y93H virus variant||8||Glecaprevir / Pibrentasvir||99%|